Skip to main content
SpringerLink
Log in

Targeted Therapies

  • Chapter
Oncology of CNS Tumors

  • 1701 Accesses

Abstract

The concept of targeted therapies has been developed in general oncology and describes the treatment of cancers according to markers or pathways that have been identified in the tumor tissue after biopsy or resection. Many of these targets have been identified by correlative studies of subgroups of patients from large cohorts of clinical trials who were segregated on the basis clinical characteristics, and there is a demand that future trials or therapies should be stratified or administered accordingly [22]. Also, targets from general oncology were extrapolated to neurooncology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aboody KS, Najbauer J, Danks MK. (2008) Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 15:739–752

    Article  PubMed  CAS  Google Scholar 

  2. Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P, Westphal M. (1993) p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer 55:982–987

    Article  PubMed  CAS  Google Scholar 

  3. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95

    Article  PubMed  CAS  Google Scholar 

  4. Belda-Iniesta C, Carpeno Jde C, Saenz EC, Gutierrez M, Perona R, Baron MG. (2006) Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther 5:912–914

    Article  PubMed  CAS  Google Scholar 

  5. Bellinzona M, Roser F, Matthies C, Samii M, Saini M. (2004) Biopolymer-mediated suramin chemotherapy in the treatment of experimental brain tumours. Acta Oncol 43:259–263

    Article  PubMed  CAS  Google Scholar 

  6. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD. (1990) Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50:8017–8022

    PubMed  CAS  Google Scholar 

  7. Board R, Jayson GC. (2005) Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat 8:75–83

    Article  PubMed  CAS  Google Scholar 

  8. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. (1994) Convection-enhanced delivery of mac-romolecules in the brain. Proc Natl Acad Sci USA 91:2076–2080

    Article  PubMed  CAS  Google Scholar 

  9. Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R. (2008) Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res 14:957–960

    Article  PubMed  CAS  Google Scholar 

  10. Cancer Genome Atlas Research Network. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068

    Article  Google Scholar 

  11. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD. (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357–361

    Article  PubMed  CAS  Google Scholar 

  12. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J. (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10:958–966

    Article  PubMed  CAS  Google Scholar 

  13. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. (2008) Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glio-blastoma. PLoS Med 5:e8

    Article  PubMed  Google Scholar 

  14. D'Abaco GM, Kaye AH. (2007) Integrins: molecular determinants of glioma invasion. J Clin Neurosci 14:1041–1048

    Article  PubMed  Google Scholar 

  15. Dai C, Lyustikman Y, Shih A, Hu X, Fuller GN, Rosenblum M, Holland EC. (2005) The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia 7:397–406

    Article  PubMed  CAS  Google Scholar 

  16. Das S, Raizer JJ, Muro K. (2008) Immunotherapeutic treatment strategies for primary brain tumors. Curr Treat Options Oncol 9:32–40

    Article  PubMed  Google Scholar 

  17. de Bouard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS. (2007) Anti-angiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 9:412–423

    Article  PubMed  Google Scholar 

  18. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW. (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098–3104

    Article  PubMed  Google Scholar 

  19. Ermoian RP, Kaprealian T, Lamborn KR, Yang X, Jelluma N, Arvold ND, Zeidman R, Berger MS, Stokoe D, Haas-Kogan DA. (2009) Signal transduction molecules in gliomas of all grades. J Neurooncol 91:19–26

    Article  PubMed  Google Scholar 

  20. Ferguson S, Lesniak MS. (2007) Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr Drug Deliv 4:169–180

    Article  PubMed  CAS  Google Scholar 

  21. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. (2008) Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 5:123–127

    Article  PubMed  Google Scholar 

  22. Fine HA. (2007) Promising new therapies for malignant gliomas. Cancer J 13:349–354

    Article  PubMed  CAS  Google Scholar 

  23. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. (2003) Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95:652–660

    Article  PubMed  CAS  Google Scholar 

  24. Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Lecluse Y, van Beusechem VW, Gerritsen WR, Kirn DH, Vassal G. (2003) Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer 89:577–584

    Article  PubMed  CAS  Google Scholar 

  25. Giese A, Bjerkvig R, Berens ME, Westphal M. (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624–1636

    Article  PubMed  CAS  Google Scholar 

  26. Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, Nozaki M, Diserens AC, Hamou MF, Dietrich P Y, Regli L, Janzer RC, Bucher P, Stupp R, de Tribolet N, Domany E, Hegi ME. (2003) Classification of human astro-cytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63:6613–6625

    PubMed  CAS  Google Scholar 

  27. Goetz CM, Rachinger W, Decker M, Gildehaus FJ, Stocker S, Jung G, Tatsch K, Tonn JC, Reulen HJ. (2005) Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats. Cancer Immunol Immunother 54:337–344

    Article  PubMed  CAS  Google Scholar 

  28. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. (2008) VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 10(6):940–945

    Article  PubMed  Google Scholar 

  29. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M, Lamszus K. (2008) Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27:2897–2909

    Article  PubMed  CAS  Google Scholar 

  30. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, Pichler J, Wurm G, Mehdorn M, Strege R, Schuierer G, Villarrubia V, Fellner F, Jansen O, Straube T, Nohria V, Goldbrunner M, Kunst M, Schmaus S, Stauder G, Bogdahn U, Schlingensiepen KH. (2007) Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17:201–212

    Article  PubMed  CAS  Google Scholar 

  31. Kargiotis O, Chetty C, Gondi CS, Tsung AJ, Dinh DH, Gujrati M, Lakka SS, Kyritsis AP, Rao JS. (2008) Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene 27:4830–4840

    Article  PubMed  CAS  Google Scholar 

  32. Kuan CT, Wikstrand CJ, Bigner DD. (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8:83–96

    Article  PubMed  CAS  Google Scholar 

  33. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K. (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothe-lial growth factor receptor-2. Cancer Res 61:6624–6628

    PubMed  CAS  Google Scholar 

  34. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK. (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837–844

    Article  PubMed  CAS  Google Scholar 

  35. Lal B, Xia S, Abounader R, Laterra J. (2005) Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 11:4479–4486

    Article  PubMed  CAS  Google Scholar 

  36. Lamszus K, Laterra J, Westphal M, Rosen EM. (1999) Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 17:517–530

    Article  PubMed  CAS  Google Scholar 

  37. Laterra JJ, Grossman SA, Carson KA, Lesser GJ, Hochberg FH, Gilbert MR. (2004) Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro Oncol 6:15–20

    Article  PubMed  Google Scholar 

  38. Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, Perry JR, Fuller GN, Baillet M. (2006) Randomized, doubleblind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 78:295–302

    Article  PubMed  CAS  Google Scholar 

  39. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K. (2006) A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12:6144–6152

    Article  PubMed  CAS  Google Scholar 

  40. Mason WP. (2008) Emerging drugs for malignant glioma. Expert Opin Emerg Drugs 13:81–94

    Article  PubMed  CAS  Google Scholar 

  41. Mellinghoff IK, Wang M Y, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu K V, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024

    Article  PubMed  CAS  Google Scholar 

  42. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME. (2008) Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26:3015–3024

    Article  PubMed  CAS  Google Scholar 

  43. Mut M, Sherman JH, Shaffrey ME, Schiff D. (2008) Cintredekin besudotox in treatment of malignant glioma. Expert Opin Biol Ther 8:805–812

    Article  PubMed  CAS  Google Scholar 

  44. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173

    Article  PubMed  CAS  Google Scholar 

  45. Ramos TC, Figueredo J, Catala M, Gonzalez S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Perez R, Lage A. (2006) Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 5:375–379

    Article  PubMed  CAS  Google Scholar 

  46. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. (2002) Phase II trial of murine (131) I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397

    Article  PubMed  CAS  Google Scholar 

  47. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. (2008) Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17:1225–1235

    Article  PubMed  CAS  Google Scholar 

  48. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. (2008) Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 8:541–553

    Article  PubMed  CAS  Google Scholar 

  49. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, 2nd, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD. (2008) A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 10:182–189

    Article  PubMed  CAS  Google Scholar 

  50. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142

    Article  PubMed  CAS  Google Scholar 

  51. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE, 2nd, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD. (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 10:320–329

    Article  PubMed  CAS  Google Scholar 

  52. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I. (2003) Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65:27–35

    Article  PubMed  Google Scholar 

  53. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. (2008) Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20(5):267–275

    Article  PubMed  CAS  Google Scholar 

  54. Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, Lamszus K. (1999) Levels of vascular endothe-lial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84:10–18

    Article  PubMed  CAS  Google Scholar 

  55. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC, Goldbrunner RH. (2008) Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vascula-ture. Brain Pathol 18:378–386

    Article  PubMed  CAS  Google Scholar 

  56. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC. (2004) Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 64:4783–4789

    Article  PubMed  CAS  Google Scholar 

  57. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287–290

    Article  PubMed  CAS  Google Scholar 

  58. Vecil GG, Lang FF. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 65:237–246, 2003

    Article  PubMed  Google Scholar 

  59. Vega EA, Graner MW, Sampson JH. (2008) Combating immunosuppression in glioma. Future Oncol 4:433–442

    Article  PubMed  CAS  Google Scholar 

  60. Voelzke WR, Petty WJ, Lesser GJ. (2008) Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol 9:23–31

    Article  PubMed  Google Scholar 

  61. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. (2007) Bevacizumab plus iri-notecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729

    Article  PubMed  CAS  Google Scholar 

  62. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, Hingorani VN, Puri RK. (2003) Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64:125–137

    PubMed  Google Scholar 

  63. Zhou Q, Guo P, Gallo JM. (2008) Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolo-mide. Clin Cancer Res 14:1540–1549

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, U. K. Eppendorf, Martinistr. 52, Hamburg, 20246, Germany

    Manfred Westphal

  2. Neurochirurgische Klinik Universitätskrankenhaus, Eppendorf, Martinistr. 52, Hamburg, 20246, Germany

    Katrin Lamszus

Authors
  1. Manfred Westphal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katrin Lamszus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfred Westphal .

Editor information

Editors and Affiliations

  1. Universitätsklinikum München Klinikum Großhadern Neurochirurgische Klinik, Marchioninistr. 15, München, 81377, Germany

    Jörg-Christian Tonn

  2. Universitätsklinikum Hamburg Krankenhaus Eppendorf Klinik und Poliklinik für Neurochirurgie, Martinistr. 52, Neurologie, Hamburg, 20246, Germany

    Manfred Westphal

  3. Division of Neurosurgery, The Hospital for Sick Children, 555 University Avenue Suite 1502, Toronto, ON, M5G 1X8, Canada

    James T. Rutka

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Westphal, M., Lamszus, K. (2010). Targeted Therapies. In: Tonn, JC., Westphal, M., Rutka, J.T. (eds) Oncology of CNS Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-02874-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-02874-8_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-02873-1

  • Online ISBN: 978-3-642-02874-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation